Sanofi Seeks Emergency Stay Blocking 340B Dispute Resolution Proceedings

Drug manufacturer Sanofi yesterday asked a federal judge in New Jersey for an emergency stay against 340B administrative dispute resolution (ADR) proceedings against it brought by health centers.

Drug manufacturer Sanofi yesterday asked a federal judge in New Jersey to stay 340B administrative dispute resolution (ADR) proceedings against it brought by health centers seeking to overturn Sanofi’s restrictions on 340B pricing when covered entities use contract pharmacies.

Read More »

In Significant Development, HRSA Assigns Panels to Review 340B Dispute Resolution Claims Against Drug Companies

HRSA confirmed yesterday that 340B program administrative dispute resolution (ADR) panels have been assigned.

The U.S. Health Resources and Services Administration (HRSA) told 340B Report yesterday in response to an inquiry that 340B program administrative dispute resolution (ADR) panels have been assigned—signaling that an unknown number of proceedings might begin on ADR petitions by

Read More »

Boehringer Ingelheim Defends its 340B Contract Pharmacy Policy After HRSA Finds it Is Unlawful

Boehringer Ingelheim disputes HRSA's Oct. 4 finding that BI’s denials of 340B discounts on its drugs when hospitals use contract pharmacies are illegal.

Drug manufacturer Boehringer Ingelheim on Tuesday disputed a federal health agency’s finding a day earlier that BI’s denials of 340B discounts on its drugs when hospitals use contract pharmacies are illegal.

Please Login or Become a

Read More »

Judge Sets Deadlines for Briefs in 340B Contract Pharmacy Antitrust Suit

U.S. Chief District Judge Elizabeth Wolford has set deadlines for briefs in a New York health center's 340B contract pharmacy antitrust lawsuit against four drug companies.

A federal district judge in Rochester, N.Y., has given four insulin and diabetes drug manufacturers until Oct. 29 to file a motion to dismiss an upstate New York health center’s lawsuit claiming the manufacturers conspired to stop offering 340B pricing

Read More »

New Judge Assigned to PhRMA’s Lawsuit Challenging Arkansas’s First-of-Its-Kind 340B Nondiscrimination Law

U.S. Senior District Judge Billy Roy Wilson has been assigned to PhRMA's lawsuit challenging Arkansas’s 340B nondiscrimination act.

A new federal district judge has been assigned to Pharmaceutical Research and Manufacturers of America’s (PhRMA) lawsuit challenging Arkansas’s 340B nondiscrimination act.

Please Login or Become a Paid Subscriber to View this Content

Read More »

Montana GOP Congressman Proposes a Host of New Conditions on 340B Hospitals

First-term U.S. Rep. Matt Rosendale (R-Mont.) has introduced a bill to impose a host of new conditions on hospital participation in the 340B drug discount program.

Montana’s at-large Republican U.S. congressman has introduced a bill to impose a host of new conditions on hospital participation in the drug discount program.

Please Login or Become a Paid Subscriber to View this Content

Read More »

Half of Congressional Black Caucus Asks CMS to End Medicare Drug Payment Cuts for 340B Hospitals

Reps. Robin Kelly (D-Ill.), left, and Lisa Blunt Rochester (D-Del.), right, led the Sept. 24 letter urging CMS to end the nearly 30% cut in Medicare Part B drug payments to 340B hospitals.

Half of the Congressional Black Caucus (CBC) has asked Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure to end the nearly 30% cut in Medicare Part B drug payments to 340B hospitals.

Please Login

Read More »

Federal Appeals Court Hears Arguments in Case Involving Walgreens’s 340B Program

The U.S. Court of Appeals for the Fourth Circuit heard arguments in J.R. v. Walgreens Boots Alliance on Sept. 22.

A federal appeals court is considering some South Carolina Walgreens customers’ claims that Walgreens, in its capacity as a 340B contract pharmacy and as a 340B contract pharmacy third-party administrator (TPA), violated their privacy rights under South Carolina law.

Read More »

Breaking: HRSA Tells Boehringer Ingelheim its 340B Contract Pharmacy Restrictions Are Illegal

HRSA informed Boehringer Ingelheim today that its restrictions on 340B pricing when hospitals use contract pharmacies are illegal.

A senior federal health official informed drug manufacturer Boehringer Ingelheim (BI) today its restrictions on 340B pricing when hospitals use contract pharmacies are illegal and must end immediately, or BI could face civil monetary penalties.

Please

Read More »
Generic selectors
Exact matches only
Search in title
Search in content